Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.27), $0.10 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.61 million versus the consensus estimate of $8.07 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'